Mutation in RFX6 gene can give rise to a new type of diabetes, found a research team at ULB Center for Diabetes Research and the Erasmus Hospital ULB
![RFX6 Gene Mutation can Lead to a New Type of Diabetes RFX6 Gene Mutation can Lead to a New Type of Diabetes](https://images.medindia.net/health-images/1200_1000/single-gene-mutation-linked-to-degenerative-disease.jpg)
‘Individuals carrying the RFX6 mutation have a high probability of developing diabetes: it can start early, before the age of 20 years’
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Scientists from the ULB Center for Diabetes Research and the Erasmus Hospital of the ULB, together with colleagues at the University of Exeter (UK), University of Helsinki (Finland) and Kyoto University (Japan), have identified a new type of diabetes caused by a mutation in the gene RFX6.![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Individuals carrying the RFX6 mutation have a high probability of developing diabetes: it can start early, before the age of 20 years, and by the age of 50 years, 80% of the patients might have developed the disease.
It is transmitted from parents to children and may affect many generations in the same family. RFX6 diabetes often requires insulin treatment because patients have reduced insulin secretion by the pancreas.
Dr. Miriam Cnop, Professor at the ULB Center for Diabetes Research and the Erasmus Hospital, identified in these patients a reduced production of the hormone GIP( Gastric Inhibitory Peptide ) that stimulates insulin secretion.
The hormone GIP is produced by the intestine after eating and is an important regulator of insulin secretion.
Advertisement
The identification of this novel disease mechanism suggests that GIP analogs ( drugs with a structure similar to GIP) may provide a novel treatment option for patients with RFX6 diabetes.
Advertisement
Source-Eurekalert